Should I buy or sell Generation Bio stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GBIO, but not buy additional shares or sell existing shares. View GBIO analyst ratings or view top-rated stocks .

What is Generation Bio's stock price target for 2024?

6 analysts have issued 12 month price objectives for Generation Bio's shares. Their GBIO share price targets range from $5.00 to $10.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 136.0% from the stock's current price. View analysts price targets for GBIO or view top-rated stocks among Wall Street analysts .

How have GBIO shares performed in 2024?

Generation Bio's stock was trading at $1.65 on January 1st, 2024. Since then, GBIO shares have increased by 105.5% and is now trading at $3.39. View the best growth stocks for 2024 here .

When is Generation Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our GBIO earnings forecast .

How were Generation Bio's earnings last quarter?

Generation Bio Co. (NASDAQ:GBIO) announced its earnings results on Wednesday, March, 6th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.12. The company earned $2.88 million during the quarter, compared to analysts' expectations of $3.05 million.

What other stocks do shareholders of Generation Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU) , NVIDIA (NVDA) , Overstock.com (OSTK) , Boeing (BA) , Pure Storage (PSTG) , Mastercard (MA) , QUALCOMM (QCOM) , Riot Platforms (RIOT) , Twilio (TWLO) and Enphase Energy (ENPH) .

When did Generation Bio IPO?

Generation Bio (GBIO) raised $126 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Generation Bio's major shareholders?

Generation Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.57%). Insiders that own company stock include Antoinette Paone, Charles A Rowland Jr, Dannielle Appelhans, Donald William Nicholson, Douglas Kerr , Evan Spiegel , Geoff Mcdonough , Jason P Rhodes , Matthew Stanton , Phillip Samayoa and Venture Associates X L Atlas. View institutional ownership trends .

How do I buy shares of Generation Bio?

Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GBIO

Generation Bio (GBIO) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free GBIO Stock Alerts

$3.13

-0.57 (-15.41%)

(As of 05:32 PM ET)

Compare

Today's Range: $3.12
▼
$3.66
50-Day Range: $1.87
▼
$4.35
52-Week Range: $0.86
▼
$6.98

Volume: 168,390 shs
Average Volume: 275,714 shs
Market Capitalization: $208.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Get Generation Bio alerts:

Generation Bio MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 136.0% Upside
$8.00 Price Target
Short Interest: Healthy
2.35% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.49
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.34) to ($1.06) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.66 out of 5 stars

Medical Sector

450th out of 930 stocks

Pharmaceutical Preparations Industry

205th out of 427 stocks

3.2

Analyst's Opinion

Consensus Rating
Generation Bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Generation Bio has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.35% of the float of Generation Bio has been sold short.
Short Interest Ratio / Days to Cover
Generation Bio has a short interest ratio ("days to cover") of 4.2.
Change versus previous month
Short interest in Generation Bio has recently decreased by 10.24%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Generation Bio does not currently pay a dividend.
Dividend Growth
Generation Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GBIO.

1.9

News and Social Media Coverage

News Sentiment
Generation Bio has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Generation Bio this week, compared to 1 article on an average week.
Search Interest
Only 8 people have searched for GBIO on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Generation Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
20.80% of the stock of Generation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
95.22% of the stock of Generation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Generation Bio are expected to grow in the coming year, from ($1.34) to ($1.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Generation Bio is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Generation Bio is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Generation Bio has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Generation Bio Stock (NASDAQ:GBIO)

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

GBIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GBIO Stock News Headlines

April 12, 2024 | americanbankingnews.com

Generation Bio (NASDAQ:GBIO) Stock Rating Reaffirmed by Needham & Company LLC

April 2, 2024 | globenewswire.com

Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 16, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 17, 2024 | finance.yahoo.com

GBIO May 2024 7.500 call

March 16, 2024 | finance.yahoo.com

GBIO Apr 2024 5.000 call

March 8, 2024 | finance.yahoo.com

Generation Bio Co Reports Full Year and Q4 2023 Financial Outcomes

March 7, 2024 | finanznachrichten.de

Generation Bio Co.: Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

March 6, 2024 | markets.businessinsider.com

GBIO Stock Earnings: Generation Bio Misses EPS, Beats Revenue for Q4 2023

April 16, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 6, 2024 | globenewswire.com

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

February 27, 2024 | globenewswire.com

Generation Bio to Present at the 2024 TD Cowen Health Care Conference

February 25, 2024 | finance.yahoo.com

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

February 23, 2024 | benzinga.com

Generation Bio Stock (NASDAQ:GBIO), Short Interest Report

February 21, 2024 | investing.com

Generation Bio Co (GBIO)

February 21, 2024 | msn.com

What Is Biohacking And Why Gen Z And Millennials Are Obsessed With It

February 6, 2024 | bizjournals.com

Generation Bio ends Waltham lease but landlord fights back

February 3, 2024 | msn.com

Generation Bio Co. Ends Lease Citing Landlord Breach

January 30, 2024 | msn.com

The booming business of discovering your biological age: This tech company will measure it starting at $400 per year

January 19, 2024 | benzinga.com

Generation Bio Stock (NASDAQ:GBIO) Dividends: History, Yield and Dates

January 17, 2024 | entrepreneur.com

Generation Z: Page 4

January 14, 2024 | msn.com

42 Tiny Observations About Gen Z Culture That Will Be Seriously Enlightening To Other Generations

January 3, 2024 | finance.yahoo.com

Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 7, 2023 | finance.yahoo.com

Charles Rowland Bought 179% More Shares In Generation Bio

December 6, 2023 | finance.yahoo.com

Director Rowland Charles A Jr Acquires 342,960 Shares of Generation Bio Co (GBIO)

November 30, 2023 | markets.businessinsider.com

JMP Securities Keeps Their Hold Rating on Generation Bio (GBIO)

November 29, 2023 | msn.com

Generation Bio cuts its payroll by 40 percent in latest restructuring move

November 29, 2023 | bizjournals.com

Moderna-partnered gene therapy firm to lay off 68, including two execs

See More Headlines

Receive GBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GBIO
CUSIP: N/A
CIK: 1733294
Web: generationbio.com
Phone: 617-655-7500
Fax: N/A
Employees: 174
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $10.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +116.2%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-126,610,000.00
Net Margins: N/A
Pretax Margin: -2,144.51%
Return on Equity: -52.29%
Return on Assets: -31.80%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.83
Quick Ratio: 6.83

Sales & Book Value

Annual Sales: $5.90 million
Price / Sales: 41.69
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.07 per share
Price / Book: 1.21

Miscellaneous

Outstanding Shares: 66,480,000
Free Float: 52,650,000
Market Cap: $245.98 million
Optionable: Optionable
Beta: 2.78

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Cameron Geoffrey McDonough M.D. (Age 54)
President, CEO & Director
Comp: $939.09k
Dr. Matthew Norkunas M.B.A. (Age 45)
M.D., Chief Financial Officer
Comp: $611.11k
Dr. Matthew Stanton Ph.D. (Age 50)
Chief Scientific Officer
Comp: $654.83k
Dr. Mark D. Angelino Ph.D. (Age 51)
Co-Founder
Dr. Robert Kotin Ph.D. (Age 68)
Co-Founder
Ms. Antoinette Paone M.B.A. (Age 45)
M.S., Chief Operating Officer
Ms. Yalonda Howze J.D. (Age 51)
Chief Legal Officer & Secretary
Ms. Jasmin Tower
Chief Human Resources Officer
Dr. Phillip Samayoa Ph.D. (Age 36)
Chief Strategy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Generation Bio stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GBIO, but not buy additional shares or sell existing shares.
View GBIO analyst ratings or view top-rated stocks.
What is Generation Bio's stock price target for 2024?: 6 analysts have issued 12 month price objectives for Generation Bio's shares. Their GBIO share price targets range from $5.00 to $10.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 136.0% from the stock's current price.
View analysts price targets for GBIO or view top-rated stocks among Wall Street analysts.
How have GBIO shares performed in 2024?: Generation Bio's stock was trading at $1.65 on January 1st, 2024. Since then, GBIO shares have increased by 105.5% and is now trading at $3.39.
View the best growth stocks for 2024 here.
When is Generation Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our GBIO earnings forecast.
How were Generation Bio's earnings last quarter?: Generation Bio Co. (NASDAQ:GBIO) announced its earnings results on Wednesday, March, 6th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.12. The company earned $2.88 million during the quarter, compared to analysts' expectations of $3.05 million.

What other stocks do shareholders of Generation Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU), NVIDIA (NVDA), Overstock.com (OSTK), Boeing (BA), Pure Storage (PSTG), Mastercard (MA), QUALCOMM (QCOM), Riot Platforms (RIOT), Twilio (TWLO) and Enphase Energy (ENPH).
When did Generation Bio IPO?: Generation Bio (GBIO) raised $126 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Generation Bio's major shareholders?: Generation Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.57%). Insiders that own company stock include Antoinette Paone, Charles A Rowland Jr, Dannielle Appelhans, Donald William Nicholson, Douglas Kerr, Evan Spiegel, Geoff Mcdonough, Jason P Rhodes, Matthew Stanton, Phillip Samayoa and Venture Associates X L Atlas.
View institutional ownership trends.
How do I buy shares of Generation Bio?: Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GBIO) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Generation Bio (GBIO) Stock Price, News & Analysis

Generation Bio MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Generation Bio Stock (NASDAQ:GBIO)

GBIO Stock Price History

GBIO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GBIO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™